Saturday, April 26, 2025

#Coronavirus Disease Research #References (by AMEDEO, April 26 '25)

 


    Am J Obstet Gynecol

  1. THEL H, Latour CD, Tsevat D, Dissanayake M, et al
    Prevalence of male and female permanent contraception and long-acting reversible contraceptives among commercially insured US population, 2010-2022.
    Am J Obstet Gynecol. 2025 Apr 18:S0002-9378(25)00230.
    PubMed        

  2. KEULS RA, Ochsner SA, O'Neill MB, O'Day DR, et al
    Single-nucleus transcriptional profiling of the placenta reveals the syncytiotrophoblast stress response to COVID-19.
    Am J Obstet Gynecol. 2025;232.
    PubMed         Abstract available


    Int J Infect Dis

  3. BERENDS MS, Homburg M, Kupers T, Meijer EN, et al
    Impact of Pre-Existing Comorbidities and Multimorbidities, Demography and Viral Variants on Post-Acute Sequelae of COVID-19 ('Long COVID') in Dutch Primary Care: A Retrospective Cohort Study.
    Int J Infect Dis. 2025 Apr 19:107912. doi: 10.1016/j.ijid.2025.107912.
    PubMed         Abstract available


    J Infect

  4. CHEN R, Hao Z, Ye J, Zhao X, et al
    Decoding Post-Mortem Infection Dynamics of SARS-CoV-2, IAV and RSV: New Insights for Public Health and Emerging Infectious Diseases Management.
    J Infect. 2025 Apr 21:106489. doi: 10.1016/j.jinf.2025.106489.
    PubMed         Abstract available


    J Med Virol

  5. CHO J, Park J, Son Y, Kim S, et al
    Post-Acute Sequelae of COVID-19 on Alopecia Areata in Individuals With Mental Illness in South Korea and Japan: A Binational Population-Based Cohort Study.
    J Med Virol. 2025;97:e70364.
    PubMed         Abstract available

  6. SENTIS C, Parraud D, Billaud G, Valette M, et al
    Performance of Subgenomic RT-PCR for Predicting SARS-CoV-2 Infectivity Compared to Genomic RT-PCR and Culture Isolation.
    J Med Virol. 2025;97:e70363.
    PubMed         Abstract available

  7. KIM TH, Son Y, Park J, Kim S, et al
    Post-Acute Sequelae of COVID-19 on Irritable Bowel Syndrome in Individuals With Mental Illness in South Korea: A Population-Based Cohort Study.
    J Med Virol. 2025;97:e70345.
    PubMed        


    J Virol

  8. DE AVILA AI, Soria ME, Martinez-Gonzalez B, Somovilla P, et al
    SARS-CoV-2 biological clones are genetically heterogeneous and include clade-discordant residues.
    J Virol. 2025 Apr 24:e0225024. doi: 10.1128/jvi.02250.
    PubMed         Abstract available

  9. MATTHEWS L, Cook J, Stephan R, Milacic M, et al
    Advancing curation of viral life cycles, host interactions, and therapeutics in Reactome.
    J Virol. 2025 Apr 23:e0202424. doi: 10.1128/jvi.02024.
    PubMed         Abstract available


    Science

  10. KUPFERSCHMIDT K
    World agrees on pandemic treaty-without the U.S.
    Science. 2025;388:344-345.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 26 '25)

 


    Antiviral Res

  1. ZHU Y, Gao Z, Feng X, Hu Y, et al
    Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.
    Antiviral Res. 2025;237:106154.
    PubMed         Abstract available

  2. BONNEUX B, Ceconi M, Stobbelaar K, Herschke F, et al
    Insights in the RSV L polymerase function and structure.
    Antiviral Res. 2025;237:106148.
    PubMed         Abstract available

  3. BRUN J, Arman BY, Hill ML, Kiappes JL, et al
    Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
    Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123.
    PubMed         Abstract available

  4. ZIAN D, Iaconis D, Nenci S, Crusco A, et al
    The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis during medical emergencies: identification of effective antiviral 3CLpro inhibitors.
    Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119.
    PubMed         Abstract available


    Eur J Epidemiol

  5. JENSEN CB, Hansen KT, Nielsen CM, Hansen SN, et al
    Cohort profile: The BiCoVac cohort - a nationwide Danish cohort to assess short and long-term symptoms following COVID-19 vaccination.
    Eur J Epidemiol. 2025;40:225-233.
    PubMed         Abstract available


    J Exp Med

  6. MATZ HC, Ellebedy AH
    Vaccination against influenza viruses annually: Renewing or narrowing the protective shield?
    J Exp Med. 2025;222:e20241283.
    PubMed         Abstract available


    J Infect Dis

  7. FURMANSKI M, Murcia PR
    Did horses act as intermediate hosts that facilitated the emergence of 1918 pandemic influenza?
    J Infect Dis. 2025 Apr 22:jiaf197. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  8. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
    Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
    J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
    PubMed         Abstract available


    N Engl J Med

  9. UYEKI TM, Dugan VG, Daskalakis DC
    Baloxavir Treatment to Reduce Influenza Virus Transmission.
    N Engl J Med. 2025;392:1652-1654.
    PubMed        

  10. MONTO AS, Kuhlbusch K, Bernasconi C, Cao B, et al
    Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.
    N Engl J Med. 2025;392:1582-1593.
    PubMed         Abstract available


    Pediatrics

  11. BASSETT HK, Rao S, Beck J, Brady PW, et al
    Variability of Clinician Recommendations for Oseltamivir in Children Hospitalized With Influenza.
    Pediatrics. 2025 Apr 25:e2024069111. doi: 10.1542/peds.2024-069111.
    PubMed         Abstract available

  12. ZHU S, Quint J, Penton C, Hoover C, et al
    Duration of Illness in Children <18 Years Dying of Influenza in California: 2004-2023.
    Pediatrics. 2025;155:e2024069368.
    PubMed        


    PLoS Comput Biol

  13. TEOH YC, Noor MS, Aghakhani S, Girton J, et al
    Viral escape-inspired framework for structure-guided dual bait protein biosensor design.
    PLoS Comput Biol. 2025;21:e1012964.
    PubMed         Abstract available

  14. WANG M, Patsenker J, Li H, Kluger Y, et al
    Supervised fine-tuning of pre-trained antibody language models improves antigen specificity prediction.
    PLoS Comput Biol. 2025;21:e1012153.
    PubMed         Abstract available


    PLoS Genet

  15. LIEFFERINCKX C, Stern D, Peree H, Bottieau J, et al
    The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk.
    PLoS Genet. 2025;21:e1011599.
    PubMed         Abstract available


    PLoS One

  16. SEDGHIAN A, MohammadEbrahimi S, Sartorius B, Kiani B, et al
    National spatiotemporal patterns of influenza-like illness in Iran: A pre-COVID-19 study (2015-2019).
    PLoS One. 2025;20:e0320990.
    PubMed         Abstract available

  17. TOMKINS AA, Dulai G, Dulai R, Rassenberg S, et al
    Measuring the fitted filtration efficiency of cloth masks, medical masks and respirators.
    PLoS One. 2025;20:e0301310.
    PubMed         Abstract available

  18. ROBINSON CC, Sganzerla D, Manfio JL, Kochhann R, et al
    Incidence, associated factors and impact of the post-COVID-19 condition in Brazil: Study protocol of an observational cohort during the Omicron phase.
    PLoS One. 2025;20:e0322466.
    PubMed         Abstract available

  19. DICKINSON R, Makowski D, van Marwijk H, Ford E, et al
    Interventions for combating COVID-19 misinformation: A systematic realist review.
    PLoS One. 2025;20:e0321818.
    PubMed         Abstract available

  20. VIJAYAKUMAR S, Louis DW, Corneau E, Erqou S, et al
    Association between pre-existing Pulmonary Hypertension and COVID-19 related outcomes in inpatient and ambulatory care settings.
    PLoS One. 2025;20:e0321964.
    PubMed         Abstract available

  21. DI CHIARA C, Ferrarese M, Boracchini R, Cantarutti A, et al
    Long-term neuropsychiatric and neuropsychological impact of the pandemic in Italian COVID-19 family clusters, including children and parents.
    PLoS One. 2025;20:e0321366.
    PubMed         Abstract available

  22. AL-SHAMALI HF, Dong R, Jackson M, Burback L, et al
    Suffering in silence: Accessing mental health care and repetitive transcranial magnetic stimulation (rTMS) for peripartum depression - A qualitative study.
    PLoS One. 2025;20:e0321813.
    PubMed         Abstract available

  23. SHABNAM S, Zaccardi F, Yates T, Islam N, et al
    COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom.
    PLoS One. 2025;20:e0319438.
    PubMed         Abstract available

  24. SPANYIK A, Simon D, Rigo A, Gacs B, et al
    Cynicism among medical students: An in-depth analysis of mental health dynamics and protective factors in medical education using structural equation modeling.
    PLoS One. 2025;20:e0321274.
    PubMed         Abstract available

  25. BRINKMAN N, Teunis T, Choi S, Ring D, et al
    Factors associated with the presence and intensity of ongoing symptoms in Long COVID.
    PLoS One. 2025;20:e0319874.
    PubMed         Abstract available

  26. BASA M, De Vries J, McDonagh D, Comiskey C, et al
    Adherence to alcohol consumption-related recommendations and predictors of heavy episodic drinking among patients with NCDs during the COVID-19 pandemic.
    PLoS One. 2025;20:e0321577.
    PubMed         Abstract available

  27. SAITO MM, Katayama K, Naruse A, Ruan P, et al
    Effects of inbound attendees of a mass gathering event on the COVID-19 epidemic using individual-based simulations.
    PLoS One. 2025;20:e0321288.
    PubMed         Abstract available

  28. SANCHEZ-IZQUIERDO M, Garcia-Sanchez R, Prieto-Ursua M, Mateos-Nozal J, et al
    Positive outcomes among nursing home caregivers in Spain during the COVID-19 pandemic: A qualitative interview study.
    PLoS One. 2025;20:e0320663.
    PubMed         Abstract available

  29. ABRAR SM, Awasthi N, Smolyak D, Sigalo N, et al
    Auditing the fairness of the US COVID-19 forecast hub's case prediction models.
    PLoS One. 2025;20:e0319383.
    PubMed         Abstract available

  30. DAWSON AJ, Bista A, Wilson AE
    Is trust a zero-sum game? What happens when institutional sources get it wrong.
    PLoS One. 2025;20:e0321743.
    PubMed         Abstract available

  31. SOUCY A, Pellecer Rivera E, Siwek N, Martin L, et al
    Opportunities and challenges within green spaces during COVID-19: Perspectives of visitors and managers in Maine, USA.
    PLoS One. 2025;20:e0320800.
    PubMed         Abstract available

  32. LEBEDEV M, Walsh P, Newman JW, Mutua VN, et al
    Immune mechanisms affected by cyclooxygenase inhibition combined with antiviral treatment in calves infected with bovine respiratory syncytial virus.
    PLoS One. 2025;20:e0321642.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  33. BONTORIN S, Centellegher S, Gallotti R, Pappalardo L, et al
    Mixing individual and collective behaviors to predict out-of-routine mobility.
    Proc Natl Acad Sci U S A. 2025;122:e2414848122.
    PubMed         Abstract available


    Vaccine

  34. HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
    Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
    Vaccine. 2025;56:127144.
    PubMed         Abstract available

  35. ZHANG X, Shi H, Ross TM
    Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
    Vaccine. 2025;56:127156.
    PubMed         Abstract available

  36. FINNEY J, Kuraoka M, Song S, Watanabe A, et al
    Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
    Vaccine. 2025;56:127157.
    PubMed         Abstract available

  37. CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
    Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
    Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
    PubMed         Abstract available

  38. BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
    Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
    Vaccine. 2025;53:127074.
    PubMed         Abstract available

  39. OLESEN SW, Holmdahl I, Ortega-Sanchez IR, Biggerstaff M, et al
    Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.
    Vaccine. 2025;53:127109.
    PubMed         Abstract available

  40. SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
    Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
    Vaccine. 2025;53:127091.
    PubMed         Abstract available

  41. SHEARN C, Postavaru GI, Hylton L, Morris H, et al
    COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
    Vaccine. 2025;53:127071.
    PubMed         Abstract available

  42. BERNARD C, Drouin J, Le Vu S, Botton J, et al
    COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
    Vaccine. 2025;53:127070.
    PubMed         Abstract available

  43. FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
    Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
    Vaccine. 2025;53:127084.
    PubMed         Abstract available

  44. FLYNN PM, Stull C, Jain VM, Evans MD, et al
    A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
    Vaccine. 2025;53:127035.
    PubMed         Abstract available

  45. FELIX P, Melo AA, Costa JP, Colaco M, et al
    Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
    Vaccine. 2025;53:127078.
    PubMed         Abstract available

  46. MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
    COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
    Vaccine. 2025;53:127050.
    PubMed         Abstract available

  47. PATRICK R, Mahale P, Ackerson BK, Hong V, et al
    Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
    Vaccine. 2025;53:127033.
    PubMed         Abstract available

  48. FORAN AM, Jetten J, Muldoon OT
    Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
    Vaccine. 2025;53:127086.
    PubMed         Abstract available

  49. KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
    A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
    Vaccine. 2025;53:127063.
    PubMed         Abstract available

  50. MEERAUS W, Postema A, Gray CM, Lee A, et al
    Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
    Vaccine. 2025;53:126955.
    PubMed         Abstract available

  51. ZHAO T, Xu Q, Cai X, Wang M, et al
    Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
    Vaccine. 2025;53:126933.
    PubMed         Abstract available

  52. KADOI K, Toba J, Uehara A, Isoda N, et al
    Enhanced sulfate pseudo-affinity chromatography using monolith-like particle architecture for purifying SARS-CoV-2.
    Vaccine. 2025;53:126951.
    PubMed         Abstract available

  53. TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
    Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
    Vaccine. 2025;53:126932.
    PubMed         Abstract available

  54. KEELING MJ, Hill EM, Petrou S, Tran PB, et al
    Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
    Vaccine. 2025;53:126948.
    PubMed         Abstract available

  55. EYAL N, Wendler D
    Assessing the risks of current COVID-19 challenge trials systematically.
    Vaccine. 2025;53:126877.
    PubMed         Abstract available


    Virus Res

  56. CHEN N, Jin J, Qiao B, Gao Z, et al
    JNK kinase promotes inflammatory responses by inducing the expression of the inflammatory amplifier TREM1 during influenza a virus infection.
    Virus Res. 2025;356:199577.
    PubMed         Abstract available

#Biosecurity uptake and perceived #risk of avian #influenza among people in #contact with #birds in the #UK

Abstract

Recent intercontinental spread of highly pathogenic avian influenza (HPAI) A(H5N1) among kept and wild birds and transmission to mammalian hosts, including cattle and humans has heightened the need to review public health risk assessments. Biosecurity is essential for limiting disease spread, but how widely practices are implemented is not fully known. Here, we report on the uptake of biosecurity measures using questionnaire data collected in 2024 from people in contact with birds in the UK (Avian Contact Study). Almost half of the sample were poultry farmers (104/225). We found hand washing after contact with birds was the most common biosecurity measure implemented (89%, 196/218), followed by using disinfecting footwear dips (78%, 170/218). Individuals in contact with a higher number of birds were more likely to use at least one PPE measure for the face or body (χ^2 (1, n=217) = 32.452, p<0.001) or at least one footwear-related PPE measure (Df=1, n=217, p<0.001), indicating the increasing number of birds as a likely proxy for farming practice, given the skewed poultry farmer sample. The perceived risk of avian influenza to the health of birds was generally high for individuals in contact with large flocks (≥1001 birds) and was associated with uptake of at least one footwear-related PPE measure (χ^2 (1, n=185)= 9.171, p=0.002). The risk to human health was not associated with any biosecurity measure. These results suggest that routinely used biosecurity measures are implemented to limit disease spread among birds, but not with the primary view to limit zoonotic transmission from birds to humans. Future work should investigate attitudes towards avian influenza and biosecurity in larger sample sizes across varying populations to guide zoonotic influenza policy and inform targeted interventions.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.04.23.25326059v1

____

The expanding avian #influenza #panzootic: #skua die-off in #Antarctica

Abstract

High pathogenicity avian influenza virus of subtype H5 (H5 HPAIV), clade 2.3.4.4b, invaded Antarctica in 2023. Here we show that H5 HPAIV caused high mortality in a breeding colony of skuas at one of ten sites we visited in March 2024. By combined virological and pathological analyses, we found that H5 HPAIV caused multi-organ necrosis and rapid death in skuas. Taken together with recent data, skuas in Antarctica are at risk of continued mortality from H5 HPAIV infection, threatening their already small populations. Conversely, because of their wide distribution and ecological relevance, skuas may play a substantial role in the spread of the virus across Antarctica. Transdisciplinary surveillance is needed in coming years to monitor the impact of this poultry-origin disease on Antarctica's unique wildlife.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.25.650384v1

____

Friday, April 25, 2025

The #bat #influenza A virus subtype #H18N11 induces nanoscale MHCII clustering upon host #cell attachment

Abstract

Prior to the discovery of bat influenza A virus (IAV) subtypes H17N10 and H18N11, all IAVs were thought to bind sialic acid residues via hemagglutinin (HA) to mediate attachment and subsequent viral entry. However, H17 and H18 engage a proteinaceous receptor: the major histocompatibility complex class II (MHCII). The mechanistic details of this hitherto unknown protein-mediated entry are not understood. Given that conventional IAVs rely on multivalent binding to sialylated glycans, we hypothesized that bat HA similarly interacts with multiple MHCII molecules. Using photoactivated localization microscopy (PALM) on fixed and live cells, we demonstrate that bat IAV particles attach to pre-existing MHCII clusters and induce a further increase in cluster size upon binding. To measure the impact of viral attachment on the dynamics of MHCII, we employ an “inverse attachment” approach, immobilizing viral particles on coverslips before seeding live MHCII-expressing cells on top. Single-molecule tracking reveals that the mobility of MHCII is indeed slowed down in viral proximity leading to a local enrichment of MHCII molecules beneath the viral particle. These findings suggest that viral attachment induces MHCII clustering, a process similar to the MHCII dynamics observed during the formation of an immunological synapse.

Source: Nature Communications, https://www.nature.com/articles/s41467-025-58834-y

____

Single #influenza A viruses induce #nanoscale cellular #reprogramming at the virus-cell interface

Abstract

During infection, individual virions trigger specific cellular signaling at the virus-cell interface, a nanoscale region of the plasma membrane in direct contact with the virus. However, virus-induced receptor recruitment and cellular activation are transient processes that occur within minutes at the nanoscale. Hence, the temporal and spatial kinetics of such early events often remain poorly understood due to technical limitations. To address this challenge, we develop a protocol to covalently immobilize labelled influenza A viruses on glass surfaces before exposing them to live epithelial cells. Our method extends the observation time for virus-plasma membrane association while minimizing viral modifications, facilitating live imaging of virus-cell interactions. Using single-molecule super-resolution microscopy, we investigate virus-receptor interaction showing that viral receptors exhibit reduced mobility at the virus-binding site, which leads to a specific local receptor accumulation and turnover. We further follow the dynamics of clathrin-mediated endocytosis at the single-virus level and demonstrate the recruitment of adaptor protein 2 (AP-2), previously thought to be uninvolved in influenza A virus infection. Finally, we examine the nanoscale organization of the actin cytoskeleton at the virus-binding site, showing a local and dynamic response of the cellular actin cortex to the infecting virus.

Source: Nature Communications, https://www.nature.com/articles/s41467-025-58935-8

____

A modelling #assessment for the #impact of #control measures on highly pathogenic avian #influenza #transmission in #poultry in Great #Britain

Abstract

Since 2020, large-scale outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in Great Britain have resulted in substantial poultry mortality and economic losses. Alongside the costs, the risk of circulation leading to a viral reassortment that causes zoonotic spillover raises additional concerns. However, the precise mechanisms driving transmission between poultry premises and the impact of potential control measures in Great Britain, such as vaccination, are not fully understood. We have developed a spatial transmission model for the spread of HPAI in poultry premises calibrated to infected premises data for the 2022--23 season using Markov chain Monte Carlo. Our results indicate that enhanced biosecurity measures and/or vaccination of the premises surrounding an identified infected premises can substantially reduce the overall number of infected premises. Our findings highlight that enhanced control measures could limit the future impact of HPAI on the poultry industry and reduce the risk of broader health threats.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.24.650264v1

____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater {as of April 25 '25}



{Excerpt}

Time Period: April 13, 2025 - April 19, 2025

-- H5 Detection4 sites (1.0%)

-- No Detection406 sites (99.0%)

-- No samples in last week153 sites




(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html?cove-tab=0

____

#Vietnam - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification



A poultry farm in Quang Tri province.

Source: WOAH, https://wahis.woah.org/#/in-review/6440

____

The #receptor binding properties of #H5Nx #influenza A viruses have evolved to promiscuously bind to avian-type mucin-like O-glycans

Abstract

Highly pathogenic H5Nx influenza A viruses are causing unprecedented, season-independent outbreaks across avian and mammalian species, including dairy cattle, a novel reservoir. The sialoside-binding properties of influenza A hemagglutinin (HA) are strongly related to its ability to infect and transmit between hosts. Mucin-like O-glycans, omnipresent in respiratory tracts, have been understudied as viral receptors due to their complexity. To address this, we synthesized 25 O-linked glycans with diverse sialosides, including modifications by fucosides and sulfates. Our findings reveal that H5Nx 2.3.4.4b viruses uniquely bind core 3 sialyl-Lewisx and Sia-Gal-β3GalNAc, glycans not recognized by classical H5 or other avian viruses. By determining its crystal structure, we resolved the structural features of both structures in an H5 hemagglutinin (HA) from a 2016 2.3.4.4b virus. While these viruses do not bind human-type receptors, their promiscuous receptor specificity enhances binding to human tracheal tissues, suggesting that O-glycan recognition contributes to their zoonotic potential.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.24.650378v1

____

Thursday, April 24, 2025

Emergence and interstate spread of highly pathogenic avian #influenza A(#H5N1) in dairy #cattle in #USA

Editor’s summary

High-pathogenicity avian influenza subtype H5N1 is now present throughout the US, and possibly beyond. More cattle infections elevate the risk of the virus evolving the capacity to transmit between humans, potentially with high fatality rates. Nguyen et al. show that from a single transmission event from a wild bird to dairy cattle in December 2023, there has been cattle-to-poultry, cattle-to-peridomestic bird, and cattle-to-other mammal transmission. The movement of asymptomatic dairy cattle has facilitated the rapid dissemination of H5N1 from Texas across the US. Evolution within cattle, assessed using deep-sequencing data, has detected low-frequency sequence variants that had previously been associated with mammalian adaptation and transmission efficiency. —Caroline Ash


Structured Abstract

INTRODUCTION

Highly pathogenic avian influenza (HPAI) viruses have critical consequences for animal health and the agricultural economy—and may have pandemic potential. HPAI related to the goose/Guangdong 2.3.4.4 hemagglutinin (HA) H5NX phylogenetic clade has spread to nearly 100 countries, and it is recognized as a panzootic. HPAI virus circulation is ongoing in North America, and after a trans-Atlantic incursion in late 2021, the HPAI H5N1 clade 2.3.4.4b virus caused widespread outbreaks. The outbreaks resulted in extensive mortality events, culling of poultry when detected in agricultural systems, and interspecies transmission events into mammals. It is critical to determine how HPAI clade 2.3.4.4b evolves in wild birds and in nonhuman mammals after spillover to assess the potential for human infection and transmission.

RATIONALE

In late January 2024, veterinarians observed dairy cattle displaying decreased feed intake and changes in milk quality and production. On 25 March 2024, HPAI H5N1 clade 2.3.4.4b was confirmed in dairy cattle in Texas. Shortly thereafter, the virus was identified in cattle in eight other United States (US) states by members of the National Animal Health Laboratory Network. The goal of this study was to analyze genetic sequence data collected after the introduction of HPAI H5N1 in late 2021 into the Atlantic flyway of North America and its onward circulation and reassortment with North American wild bird–origin low-pathogenicity viruses. These data were combined with whole-genome sequence data and epidemiological information from the HPAI H5N1 outbreak among US dairy cattle to help us understand when the interspecies transmission event to cattle occurred and the consequences of animal movement for virus spread.

RESULTS

H5N1 clade 2.3.4.4b genotype B3.13 influenza A virus was confirmed in milk with limited detections in nasal swabs. The initial outbreak included samples from 26 dairy cattle premises across eight states and six poultry premises in three states. The sequences isolated from cattle clustered within a single group in phylogenetic analyses, supporting a single spillover event in late 2023. A reassortment event preceded the spillover, and after introduction, the virus persisted in cattle with evidence for transmission from cattle into poultry and peridomestic animal species. Epidemiological records and phylodynamic modeling documented that the movement of asymptomatic or presymptomatic dairy cattle resulted in the dissemination of the virus across the US. We identified low-frequency within-host sequence variants across the genome that were associated with changes in virulence, host-range specificity, and mammalian adaptation.

CONCLUSION

A single wild bird-to-cattle transmission event of HPAI H5N1 clade 2.3.4.4b occurred in late 2023. The spillover was likely preceded by a reassortment event in wild bird populations followed by the movement of cattle that spread HPAI within the US dairy herd. Molecular markers that may lead to changes in transmission efficiency and phenotype were detected at low frequencies. Continued transmission of H5N1 HPAI within dairy cattle increases the risk for infection and subsequent spread of the virus to humans and other host populations.


Abstract

Highly pathogenic avian influenza (HPAI) viruses cross species barriers and have the potential to cause pandemics. In North America, HPAI A(H5N1) viruses related to the goose/Guangdong 2.3.4.4b hemagglutinin phylogenetic clade have infected wild birds, poultry, and mammals. Our genomic analysis and epidemiological investigation showed that a reassortment event in wild bird populations preceded a single wild bird–to-cattle transmission episode. The movement of asymptomatic or presymptomatic cattle has likely played a role in the spread of HPAI within the United States dairy herd. Some molecular markers that may lead to changes in transmission efficiency and phenotype were detected at low frequencies. Continued transmission of H5N1 HPAI within dairy cattle increases the risk for infection and subsequent spread of the virus to human populations.

Source: Science, https://www.science.org/doi/10.1126/science.adq0900

____

#Seroprevalence of #H9N2 and #H5 avian #influenza in mixed-species #poultry #farms in Northern #Benin

ABSTRACT

Avian influenza is one of the major threats to poultry and human health in northern Benin, while mixed-species farming systems increase the risks of viral transmission. The present study estimated the seroprevalence of avian influenza subtypes H9N2 and H5 in indigenous chickens and guinea fowls in the Atacora and Donga regions. A total of 300 birds including 191 indigenous chickens and 109 guinea fowls, from six districts were sampled through a cross-sectional survey using systematic random sampling. Hemagglutination inhibition assay was used to detect antibodies, revealing an overall H9N2 seroprevalence of 41%, with 17.5% of samples testing positive for H5. The seroprevalence of H9N2 was notably higher in guinea fowls (51.81% in Atacora and 52% in Donga) compared to chickens (34.95% in Atacora and 34.83% in Donga). H5 antibodies were found only in guinea fowls in Atacora (46.66%). The study also found that farms with both chickens and guinea fowls had a significantly higher odds ratio for H9N2 positivity (OR = 4.25, p < 0.001) compared to chicken-only farms. The results underscore the importance of mixed-species systems in the transmission of avian influenza, suggesting that targeted surveillance and biosecurity measures are essential for controlling the spread of these viruses.

Source: Journal of Immunoassay and Immunochemistry, https://www.tandfonline.com/doi/full/10.1080/15321819.2025.2496480

____

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus

Abstract

In 2018, a clinical trial of four investigational therapies for Ebola virus disease (EVD), known as the PALM trial, was conducted in the Democratic Republic of Congo. All patients received either the antiviral remdesivir (RDV) or a monoclonal antibody product: ZMapp, mAb114 (Ebanga), or REGN-EB3 (Inmazeb). The study concluded that both mAb114 and REGN-EB3 were superior to ZMapp and RDV in reducing mortality from EVD. However, the data suggested that some patients in the RDV and ZMapp groups might have been sicker at the time of treatment initiation. Here, we assessed the efficacy of each of these therapies in a uniformly lethal rhesus monkey model of EVD when treatment was initiated 5 days after Ebola exposure. Treatment with RDV, mAb114, REGN-EB3, and ZMapp each resulted in similar survival (approximately 40%). Survival was associated with circulating viral load at treatment initiation. A trend of more escape mutants in the GP1 and GP2 domains was observed for the mAb114 group. Our data show similar suboptimal efficacy of individual therapeutics in the uniformly lethal NHP model of EVD, supporting further clinical investigation of therapeutic combinations to maximize the overall therapeutic effect and improve patient outcomes, particularly for the treatment of advanced stage EVD.

Source: Nature Communications, https://www.nature.com/articles/s41467-025-59168-5

____

Investigating #Factors Driving Shifts in #Subtype #Dominance within #H5Nx Clade 2.3.4.4b High-Pathogenicity Avian #Influenza viruses

Abstract

H5Nx clade 2.3.4.4b high-pathogenicity avian influenza viruses (HPAIVs) have decimated wild bird and poultry populations globally since the autumn of 2020. In the United Kingdom (UK) and in continental Europe, the H5N8 subtype predominated during the first epizootic wave of 2020/21, with few detections of H5N1. However, during the second (2021/22) and third (2022/23) epizootic waves, H5N1 was the dominant subtype. The rapid shift in dominance from H5N8 to H5N1 was likely driven by a combination of virological, immunological, and/or host-related factors. In this study, we compared viral fitness and immunological responses in ducks, a key reservoir species, using dominant genotypes of H5N1 (genotype AB) and H5N8 (genotype A) from the second wave. While viral shedding dynamics were similar for both viruses, H5N8 was more pathogenic. Antigenic analysis of post-infection duck sera revealed that the haemagglutinin (HA) protein was antigenically similar across clade 2.3.4.4b H5 HPAIVs, but neuraminidase (NA) proteins displayed different patterns of cross-reactivity. We also modelled a scenario where ducks were pre-exposed to H5N1 (genotype C) or H5N8 (genotype A) from the first wave and subsequently challenged with either homologous or heterologous subtypes from the second wave (genotype AB or A). Despite the absence of seroconversion, pre-exposure to different subtypes resulted in varying clinical outcomes following challenge. These findings indicate that both viral and immunological factors likely played significant roles in the emergence and spread of H5Nx HPAIVs in wild bird populations.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.23.650244v1

____

Efficacy of #Baloxavir #Treatment in Preventing #Transmission of #Influenza

Abstract

Background

Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown sufficient evidence that they prevent transmission to contacts.

Methods

We conducted a multicountry, phase 3b trial to assess the efficacy of single-dose baloxavir treatment to reduce influenza transmission from index patients to household contacts. Influenza-positive index patients 5 to 64 years of age were randomly assigned in a 1:1 ratio to receive baloxavir or placebo within 48 hours after symptom onset. The primary end point was transmission of influenza virus from an index patient to a household contact by day 5. The first secondary end point was transmission of influenza virus by day 5 that resulted in symptoms.

Results

Overall, 1457 index patients and 2681 household contacts were enrolled across the 2019–2024 influenza seasons; 726 index patients were assigned to the baloxavir group, and 731 to the placebo group. By day 5, transmission of laboratory-confirmed influenza was significantly lower with baloxavir than with placebo (adjusted incidence, 9.5% vs. 13.4%; adjusted odds ratio, 0.68; 95.38% confidence interval [CI], 0.50 to 0.93; P=0.01), with an adjusted relative risk reduction of 29% (95.38% CI, 12 to 45). The adjusted incidence of transmission of influenza virus by day 5 that resulted in symptoms was 5.8% with baloxavir and 7.6% with placebo; however, the difference was not significant (adjusted odds ratio, 0.75; 95.38% CI, 0.50 to 1.12; P=0.16). Emergence of drug-resistant viruses during the follow-up period occurred in 7.2% (95% CI, 4.1 to 11.6) of the index patients in the baloxavir group; no resistant viruses were detected in household contacts. No new safety signals were identified.

Conclusions

Treatment with a single oral dose of baloxavir led to a lower incidence of transmission of influenza virus to close contacts than placebo. (Funded by F. Hoffmann–La Roche and others; CENTERSTONE ClinicalTrials.gov number, NCT03969212.)

Source: The New England Journal of Medicine, https://www.nejm.org/doi/full/10.1056/NEJMoa2413156?query=TOC

____

Wednesday, April 23, 2025

#Geographic and #age #variations in mutational processes in #colorectal #cancer

Abstract

Colorectal cancer incidence rates vary geographically and have changed over time1. Notably, in the past two decades, the incidence of early-onset colorectal cancer, affecting individuals under the age of 50 years, has doubled in many countries2-5. The reasons for this increase are unknown. Here, we investigate whether mutational processes contribute to geographic and age-related differences by examining 981 colorectal cancer genomes from 11 countries. No major differences were found in microsatellite unstable cancers, but variations in mutation burden and signatures were observed in the 802 microsatellite-stable cases. Multiple signatures, most with unknown etiologies, exhibited varying prevalence in Argentina, Brazil, Colombia, Russia, and Thailand, indicating geographically diverse levels of mutagenic exposure. Signatures SBS88 and ID18, caused by the bacteria-produced mutagen colibactin6,7, had higher mutation loads in countries with higher colorectal cancer incidence rates. SBS88 and ID18 were also enriched in early-onset colorectal cancers, being 3.3 times more common in individuals diagnosed before age 40 than in those over 70, and were imprinted early during colorectal cancer development. Colibactin exposure was further linked to APC driver mutations, with ID18 responsible for about 25% of APC driver indels in colibactin-positive cases. This study reveals geographic and age-related variations in colorectal cancer mutational processes, and suggests that early-life mutagenic exposure to colibactin-producing bacteria may contribute to the rising incidence of early-onset colorectal cancer.

Source: Nature, https://www.nature.com/articles/s41586-025-09025-8

____

#HK CHP investigates severe #paediatric case of #COVID19 co-infected with human #metapneumovirus

{Excerpt}

The Centre for Health Protection (CHP) of the Department of Health today (April 23) received a report of a case of severe paediatric COVID-19 and human metapneumovirus (hMPV) infection and reminded the public to observe personal, hand and environmental hygiene at all times. High-risk individuals should receive a COVID-19 vaccination as soon as possible and receive booster doses at appropriate times to minimise the risk of serious complications and death after infection.

The case involves an eight-month-old girl with good past health, who developed a fever and runny nose since April 19 and sought medical attention from a private doctor the next day. She developed cough and shortness of breath on April 21 and sought medical attention from another private doctor. She attended the Accident and Emergency Department of Hong Kong Adventist Hospital – Tsuen Wan on April 22 and was transferred to the Paediatric Intensive Care Unit of Princess Margaret Hospital for treatment on the same day. Her respiratory specimen tested positive for SARS-CoV-2 virus and hMPV upon laboratory testing. The clinical diagnosis was COVID-19 co-infectedwith hMPV complicated with croup. She is still hospitalised and is in critical condition.

A preliminary investigation revealed that the patient had not received COVID-19 vaccine and had no travel history during the incubation period. Two of her household contacts had presented with respiratory symptoms and had recovered.

(...)

Source: Centre for Health Protection, HK PRC SAR, https://www.info.gov.hk/gia/general/202504/23/P2025042300628.htm

____

Did #horses act as intermediate #hosts that facilitated the emergence of 1918 #pandemic #influenza?

Abstract

The ecological factors that led to the 1918 influenza pandemic remain unknown. We hypothesise that horses acted as intermediate hosts spreading a pre-pandemic avian-origin virus before 1918. This is supported by reports describing a large epizootic of unusually severe equine influenza beginning in 1915. Furthermore, the high horse demand during WWI resulted in one of the biggest equine mobilisations in North America between 1914 and 1918. This extensive movement of horses provided abundant opportunities for virus reassortment between pre-pandemic avian and human influenza viruses. Archived equine tissues or serum samples will be needed to test this hypothesis.

Source: Journal of Infectious Diseases, https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiaf197/8115353?redirectedFrom=fulltext&login=false

____

#Risk #assessment of 2024 #cattle #H5N1 using age-stratified #serosurveillance data

ABSTRACT

The highly pathogenic avian influenza virus A(H5N1) clade 2.3.4.4b has caused a human outbreak in North America since March 2024. Here, we conducted a serosurveillance study to determine the risk of A(H5N1) clade 2.3.4.4b (2024 cattle H5N1) to general population. In the initial screening of 180 serum specimens encompassing all age groups, 2.2% (4/180) had detectable neutralizing antibody (nAb) titers against reverse genetics-derived 2024 cattle H5N1, with all collected from older adults aged ≥60 years old. Further screening showed that 4.2% (19/450) of adults aged ≥60 years old had detectable nAb titers against the 2024 cattle H5N1. 80% (4/5) serum specimens with nAb titer of ≥40 had detectable HI titer, and there was a positive correlation between nAb titer and HA binding (r = 0.3325, 95% confidence interval 0.2477 to 0.4123; P < 0.0001). The nAb titer against seasonal H1N1 virus was 4.2-fold higher for ≥60 years old individuals with detectable H5N1 nAb titer than those ≥60 years old ones without (geometric mean titer: 89.3 [95% CI 42.9-185.7]) vs 21.3 [95% CI 17.3-26.1], P < 0.0001), but there was no statistically significant difference between H5N1 and H3N2 nAb titer. There was no difference in demographics, comorbidities and clinical frailty scores between individuals with detectable H5N1 nAb and those without. Our findings suggest that most individuals lack nAb response against 2024 cattle H5N1 and there is an urgency to develop and evaluate H5N1 vaccine or prophylactic monoclonal antibodies. Immune imprinting may be responsible for the cross neutralization between H5N1 and H1N1 among older adults.

Source: Emerging Microbes and Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2497304

____

High Prevalence of #Influenza D Virus #Infection in #Swine, Northern Ireland

Abstract

We detected influenza D virus in multiple swine herds in Northern Ireland. Whole-genome sequencing showed several circulating genotypes and novel mutations in the receptor-binding site and esterase domains of the hemagglutinin-esterase fusion protein. Transmission routes of influenza D virus to swine remain to be clarified but could be direct or indirect.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/5/24-1948_article

____

My New Space

Most Popular Posts